treatment

The U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) has cleared Pheno Therapeutics to initiate a first-in-human Phase 1 clinical trial to test its oral candidate PTD802 in healthy volunteers. The therapy is a selective small molecule antagonist, or inhibitor, of the GPR17 receptor and is designed to restore…

TG Therapeutics is working to develop a subcutaneous, or under-the-skin, version of Briumvi (ublituximab-xiiy), its approved therapy for relapsing forms of multiple sclerosis (MS). The company said it plans to start a pivotal clinical program this year which could support an application seeking approval of the…

I’ve written several times before about how unpleasant it was to catch giardia while serving in Afghanistan with the U.S. Army, but I wasn’t the only person to get sick from drinking contaminated water. On one mission, we’d gotten up far too early to make coffee and had some…

Patient enrollment has been completed ahead of schedule in a Phase 2 clinical trial evaluating Contineum Therapeutics‘ PIPE-307, an oral therapy aiming to restore myelin — a process known as remyelination — in people with relapsing-remitting multiple sclerosis (RRMS), the company announced. The VISTA trial (NCT06083753), launched…

Immunic Therapeutics says it remains “on track” in testing its multiple sclerosis treatment candidate vidofludimus calcium in twin Phase 3 clinical trials with people who have relapsing disease — and in the Phase 2 CALLIPER study involving those with progressive forms of MS. Indeed, in a new company…

OCS-05, an experimental medication that Oculis is developing to treat acute optic neuritis, a common symptom of multiple sclerosis (MS) that can lead to vision loss, was well tolerated and improved measures of vision and eye health in a Phase 2 clinical trial. The ACUITY study (NCT04762017) included…

IRX4204, a compound that Io Therapeutics is developing to treat neurological diseases, facilitated myelin repair and improved walking abilities in a mouse model of multiple sclerosis (MS) in a recent study, scientists report. “Our findings support the therapeutic potential of IRX4204 to promote functional neurologic recovery in…

Treatment with Tecfidera (dimethyl fumarate) significantly reduces relapse rates for people with multiple sclerosis (MS), and most MS patients on the approved therapy remain free from disability progression for several years. That’s according to a final analysis from the Phase 4 ESTEEM clinical trial (NCT02047097), which tracked…

Most treatments for multiple sclerosis (MS) don’t increase the risk of major problems when used during pregnancy, an analysis showed. “We found that most therapies were not associated with an increased risk of miscarriage, premature birth or major birth defects,” Kerstin Hellwig, MD, study co-author and MS specialist at…

Men with multiple sclerosis (MS) who started on high-efficacy disease-modifying therapies (DMTs) experienced significantly fewer relapses than those who started with moderate-efficacy DMTs, according to real-world claims analysis involving more than 10,000 U.S. patients. “No significant difference in relapse was found among females,” researchers wrote. “This observation highlights…

IMP761, an experimental immunotherapy Immutep is developing for multiple sclerosis (MS) and other autoimmune conditions, has shown a promising safety profile in an ongoing Phase 1 clinical trial  in healthy volunteers, with no treatment-related side effects reported to date, the company said. The first-in-human Phase 1 trial…

About four in five adults with stable multiple sclerosis (MS) for at least five years remained free of disease activity after stopping first-line treatment with a disease-modifying therapy (DMT), according to a study based on data from the DOT-MS clinical trial. Still, disease activity reemerged in roughly 20%…

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to Sanofi’s BTK inhibitor candidate tolebrutinib for the treatment of adults with nonrelapsing secondary progressive multiple sclerosis (SPMS). According to Sanofi, tolebrutinib is the first investigational BTK inhibitor with the ability to reach the brain…

I was diagnosed with multiple sclerosis (MS) in 2014. Over the past 10 years, my MS has been managed by five healthcare providers. That’s not how I envisioned my MS care. I’ve had the same primary care provider for almost 20 years, and I naively thought I’d be…

Bionxt Solutions is preparing to launch a pilot clinical trial to compare BNT23001, its new sublingual, or under-the-tongue, formulation of cladribine, to the original medication Mavenclad to treat multiple sclerosis (MS). Mavenclad is a tablet formulation of cladribine that’s approved for adults with relapsing forms of MS. The…

Nabiximols and other cannabis-based preparations sometimes used with multiple sclerosis (MS) appear to work well for controlling spasticity, a common disease symptom that occurs when muscles stiffen or tighten, a meta-analysis of findings in published studies reported. Larger studies into cannabis-based treatments of spasticity for these patients…

Tiziana Life Sciences is expanding its Phase 2 clinical trial testing foralumab nasal spray for the treatment of nonactive secondary progressive multiple sclerosis (SPMS), with six additional clinical sites across the northeastern region of the U.S. The new sites, all at top U.S. institutions, bring together leaders in…

People with multiple sclerosis (MS) who undergo an autologous hematopoietic stem cell transplant (HSCT) — which uses a patient’s own stem cells — face unique physical and emotional challenges at every stage of the process, from balancing hope and fear when deciding on moving forward with the treatment…

Roche signed a definitive agreement to acquire Poseida Therapeutics, a deal that includes Poseida’s portfolio of CAR T-cell therapy candidates being developed for multiple sclerosis (MS) and other diseases. Poseida and Roche have been collaborating since 2022 on cell therapies for people with blood cancer. The companies…

Adding noninvasive brain stimulation to physical therapy may help people with multiple sclerosis (MS) improve their balance and walking ability, a study shows. Benefits to physical therapy with and without brain stimulation were observed, but most only remained significant after six months in those who’d also received brain stimulation.

LPX-TI641, Lapix Therapeutics‘ experimental oral therapy to restore immune system balance in people with multiple sclerosis (MS) and other autoimmune diseases, was found safe and well tolerated at all doses tested in healthy adults. That’s according to top-line data from a Phase 1 trial (NCT05853835), which…

Fampyra (fampridine), an oral medication that’s approved to improve walking ability in adults with multiple sclerosis (MS), may also help some people with poor working memory, according to a new study. Working memory refers to a person’s ability to keep small pieces of information at the forefront of…

Percutaneous tibial nerve stimulation (PTNS), a nonsurgical treatment that delivers mild electrical impulses to a nerve in the ankle, significantly reduced bladder activity and improved sexual function for women with relapsing-remitting multiple sclerosis (RRMS), according to a clinical trial. While PTNS is designed to modulate neural mechanisms involved in…

A first group of healthy adults has been dosed in a Phase 1 safety and tolerability trial of Lucid-21-302, a potential myelin-protective oral treatment for multiple sclerosis (MS), regardless of disease type. These initial volunteers will serve as the trial’s sentinels, an occasional study feature allowing for a…

Developing a more comprehensive understanding of the interactions between the brain, blood vessels, and the immune system holds great promise for unlocking new ways to treat neurological diseases like multiple sclerosis (MS), a team of researchers argued in a new commentary paper. “Interactions between the brain, blood vessels, and…

The rate of disability progression among people with relapsing-remitting multiple sclerosis (RRMS) has slowed over the years due to advances in disease-modifying therapies (DMTs), according to a long-term analysis. Patients diagnosed in recent decades have experienced fewer progression events associated with relapses, called relapse-associated worsening (RAW), and also…

Researchers at the Oregon Health & Science University have discovered a plant-derived small molecule that can promote the growth of cells that produce myelin, the protective coating around nerve fibers that’s damaged in multiple sclerosis (MS). The naturally occurring molecule, sulfuretin, blocks the activity of an enzyme that…

Increased production of cholesterol by stem cells in the brain contributes to neurological damage in multiple sclerosis (MS), according to a new study conducted in lab-grown cells. Findings suggest cholesterol-lowering medications can reverse this damage, implying such treatments might be able to be repurposed for MS. “Cholesterol metabolism has…

An independent data monitoring committee has recommended that the twin ENSURE Phase 3 trials testing vidofludimus calcium in people with relapsing forms of multiple sclerosis (MS) continue as planned without adjustments. The opinion that the trials are worth continuing was based on a review of interim, unblinded trial…

Treatment with modafinil, a medication used to reduce excessive sleepiness, and cognitive behavioral therapy (CBT) can both provide clinically meaningful reductions in fatigue in people with multiple sclerosis (MS), a new study reports. Combining modafinil with CBT, a form of talk therapy, wasn’t more effective for MS-related fatigue than…